MCM2
Overview
MCM2 is a component of the MCM2-7 DNA helicase complex required for eukaryotic DNA replication initiation. As a proliferation marker, MCM2 protein expression has been validated as an immunohistochemical (IHC) biomarker for high-risk meningioma molecular subgroups.
Alterations observed in the corpus
- MCM2 protein validated by IHC as a marker for MG4 (proliferative, highest-risk) meningioma molecular group; specific IHC marker within the four-protein panel (S100B for MG1, SCGN for MG2, ACADL for MG3, MCM2 for MG4) enabling molecular group assignment in routine neuropathology settings PMID:34433969.
- MCM2 mRNA expression was elevated in STLMS iCluster C1 (worse prognosis) vs C2 sarcomas (adjusted pā¤0.03), suggesting a role for enhanced DNA replication activity in aggressive leiomyosarcoma PMID:29100075
Cancer types (linked)
- Meningioma (MG4 molecular group) ā MCM2 IHC positivity marks the proliferative, highest-risk MG4 subgroup; MG4 is associated with worst recurrence outcomes, outperforming WHO grading PMID:34433969.
Co-occurrence and mutual exclusivity
- MG4 meningiomas with high MCM2 protein expression also show enrichment for FOXM1 and MYC transcription factor networks PMID:34433969.
Therapeutic relevance
- MG4 meningiomas (high MCM2 expression) show selective in vitro and in vivo sensitivity to vorinostat (HDAC inhibitor), warranting further clinical investigation PMID:34433969.
Open questions
- Independent validation of the four-marker IHC panel (including MCM2) is needed before clinical implementation; single-institution data only.
Sources
This page was processed by crosslinker on 2026-04-11. - PMID:29100075
This page was processed by wiki-cli on 2026-05-15.